Aug 14, 2025 | False Claims Act, federal investigations
The federal False Claims Act (FCA) allows private whistleblowers (known as “Relators”) who have knowledge of FCA violations to file lawsuits on behalf of the government and, in exchange, receive between 15% and 30% of the government’s eventual...
Aug 14, 2025 | False Claims Act, federal investigations, Health Care, Health Care Fraud, Healthcare Transactions
The federal False Claims Act (FCA) represents one of – if not the – top regulatory and liability risk that healthcare providers face when doing business with federal healthcare programs (FHPs) including Medicare and Medicaid. The FCA prohibits, among other things,...
Aug 8, 2025 | False Claims Act
On July 25, 2025, the Eleventh Circuit Court of Appeals issued an important opinion in a False Claims Act (FCA) qui tam case styled United States ex rel. Sedona Partners LLC v. Able Moving & Storage Inc., et al. (No. 22-13340). Eleventh Circuit Judge Jill Pryor,...
Jul 31, 2025 | False Claims Act, Fraud Investigations, Government Contract
As we write about regularly, the False Claims Act (FCA) is the government’s most powerful civil fraud-fighting tool, giving the government the ability to conduct sweeping investigations and pursue treble (3x) damages and per-claim penalties. Moreover, the...
Jul 30, 2025 | Uncategorized
The U.S. Food and Drug Administration is moving to restrict 7-hydroxymitragynine (7-OH), a derivative of the kratom plant that is commonly sold online and in vape stores. Citing concerns that 7-OH has opioid-like effects and could be similarly addictive, Health...
